Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-13
2007-02-13
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S156000
Reexamination Certificate
active
10492833
ABSTRACT:
An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
REFERENCES:
patent: 3472859 (1969-10-01), Lesher
patent: 5519016 (1996-05-01), Kimura et al.
patent: 5688791 (1997-11-01), Kimura et al.
patent: 5985894 (1999-11-01), Clemence et al.
patent: 6034086 (2000-03-01), Kimura et al.
patent: 6248736 (2001-06-01), Turner et al.
patent: 6248738 (2001-06-01), Dickinson et al.
patent: 6559145 (2003-05-01), Ciske et al.
patent: 2004/0127708 (2004-07-01), Fuji et al.
patent: 2004/0198716 (2004-10-01), Arad et al.
patent: 498721 (1992-08-01), None
patent: 1140851 (2001-10-01), None
patent: 1375486 (2004-01-01), None
patent: A 48 26 772 (1973-04-01), None
patent: A 43 60 872 (1992-12-01), None
patent: 6-116241 (1994-04-01), None
patent: 6-199635 (1994-07-01), None
patent: 6-271568 (1994-09-01), None
patent: 8-183776 (1996-07-01), None
patent: 10-316570 (1998-12-01), None
patent: 2002-293745 (2002-10-01), None
patent: A 2002-534416 (2002-10-01), None
patent: A 2002-534417 (2002-10-01), None
patent: WO 97/38999 (1997-10-01), None
patent: WO98/45269 (1998-10-01), None
patent: WO 00/001714 (2000-01-01), None
patent: WO 00/40561 (2000-07-01), None
patent: WO 00/40563 (2000-07-01), None
patent: WO 01/98275 (2001-12-01), None
patent: WO 02/004444 (2002-01-01), None
patent: WO 02/36734 (2002-05-01), None
patent: WO 02/55079 (2002-07-01), None
patent: WO 02/070486 (2002-09-01), None
patent: WO 02/076939 (2002-10-01), None
Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescent, pp. i-iii and 1-111, (Aug. 13, 2001).
Hirao, I. et al.,Studies on the Synthesis of Quinoline Compounds, I. Memoirs Kyushu Inst. Tech. (Eng.), 14:13-16 (1984).
Hirao, I. et al.,Antibacterial Activities of Oxodihydroquinoline Carboxylic Acid Derivatives, Memoirs Department of Engineering, 14:21-32 (1990).
Vincent, K.A., et al.,Characterization of Human Immunodeficiency Virus Type I Integrase Expressed in Eschericia coli and Analysis of Variants with Amino-Terminal Mutations, J. Virol. 67: 425-437 (1993).
Ab dul-Ahad, Europ Jor Med Chem, 17(4) pp. 301-306, 1982.
Yoshimoto, J Med Chem, 19(1.) pp. 71-98, 1976.
Baker, J Med Chem, 15(3) pp. 235-237, 1972.
Walton, Antimicrobial Agents & Chemotherapy 32(7) pp. 1086-1089, 1988.
Stefaurich, Farmaro, Edizioie Scientifica 42(1) pp. 3-16, 1987.
Search Report from Austrian Patent Office dated Apr. 3, 2006.
Aramaki Hisateru
Itoh Yoshiharu
Kawakami Hiroshi
Matsuzaki Yuji
Motomura Takahisa
Finnegan Henderson Farabow Garrett & Dunner LLP
Japan Tobacco Inc.
Seaman D. Margaret
LandOfFree
4-oxoquinoline compound and use thereof as pharmaceutical agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-oxoquinoline compound and use thereof as pharmaceutical agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-oxoquinoline compound and use thereof as pharmaceutical agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857915